PAI
TSHA icon

Palo Alto Investors’s Taysha Gene Therapies TSHA Stock Holding History

Palo Alto Investors’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.22M Buy
1,391,382
+208,187
+18% +$968K 0.95% 27
2025
Q4 		$6.51M Sell
1,183,195
-62,838
-5% -$305K 0.91% 25
2025
Q3 		$4.07M Hold
1,246,033
– – 0.75% 26
2025
Q2 		$2.88M Sell
1,246,033
-173,435
-12% -$377K 0.61% 25
2025
Q1 		$1.97M Buy
1,419,468
+608,200
+75% +$1.02M 0.38% 29
2024
Q4 		$1.4M Hold
811,268
– – 0.22% 33
2024
Q3 		$1.63M Hold
811,268
– – 0.21% 31
2024
Q2 		$1.82M Hold
811,268
– – 0.21% 31
2024
Q1 		$2.33M Buy
811,268
+281,407
+53% +$586K 0.26% 30
2023
Q4 		$938K Buy
+529,861
New +$1.06M 0.08% 31

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Palo Alto Investors's TSHA Position: Q1 2026 in Review

Palo Alto Investors increased its Taysha Gene Therapies (TSHA) stake by 18% in Q1 2026, buying an estimated $968K and bringing the position to 1,391,382 shares worth $6.22M. The position accounts for 0.95% of the portfolio, ranked #27.

Palo Alto Investors first reported a position in TSHA in Q4 2023 and has held it in 10 quarters since. The position peaked at $6.51M in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Palo Alto Investors held 1,391,382 shares of Taysha Gene Therapies worth $6.22M as of Q1 2026.
  • Palo Alto Investors bought 208,187 Taysha Gene Therapies shares in Q1 2026, an estimated $968K.
  • Taysha Gene Therapies made up 0.95% of Palo Alto Investors's portfolio in Q1 2026, its #27 holding.
  • Palo Alto Investors first reported a position in Taysha Gene Therapies in Q4 2023 and has held it in 10 quarters since.
  • Palo Alto Investors's Taysha Gene Therapies position peaked at $6.51M in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Palo Alto Investors's 13F filing for Q1 2026, filed 15 May 2026.